Click here to go to the previous page
Evaluating Sites for Optimum Site Selection and Performance
Program Code:
266
Date:
Tuesday, June 25, 2013
Time:
4:00 PM to 5:30 PM
EST
CHAIR
:
Scott R Martin,
JD,MA (SCHNON), Principal,
KMR Group Inc., United States
Scott Martin is Principal of KMR Group a firm specializing on biopharmaceutical R&D performance, information and analytics. His areas of expertise include clinical development performance, R&D productivity, and enrollment optimization. Scott received his JD from the University of Chicago.
|
SPEAKER
(S):
Scott R Martin, JD,MA (SPKNON), Principal
Douglas A Swain, RPh (SPKNON), Senior Functional Manager, Northeast Region, Genentech, A Member of the Roche Group, United States
Elizabeth Desrosiers,
MS,PMP (SPKNON), Director, Global Trial Management,
Merck Research Laboratories, United States
Elizabeth Desrosiers, PMP, has been employed by Merck for the past 20 years where she is Director, Global Trial Optimization. She has responsibility for the feasibility assessment and execution of clinical trials across the Merck portfolio. Elizabeth received her MS in Zoology from Miami University.
|
Description
The session highlights how site metrics can be used to reduce risk, shorten timelines and increase productivity in clinical trials. We will explore best practices in the use of site metrics for global site selection. We will identify ways site metrics can assist in shaping strategy, defining site goals and setting timelines to meet enrollment objectives. We will also explore how quantitative analysis of performance criteria can impact the success of your sites, and your trial.